Omekord-Mick

General characteristics. Structure:

Active ingredient: 500 mg of omegas-3-acids of ethyl ethers (ethyl ether of eykozapentayenovy acid – 46%, ethyl ether of dokozageksayenovy acid – 38%).

Excipients: alpha tocopherol.

Structure of a cover of the capsule: gelatin, глицерол, Natrium benzoicum, the water purified.

Hypolipidemic means on the basis of omegas-3-acids.

Pharmacological properties:

The Omekord-Mick capsules - hypolipidemic means on the basis of omegas-3-acids. Polyunsaturated fatty acids of a class omega-3-eykozapentayenovaya acid (EPK) and dokozageksayenovy acid (DGK) belong to irreplaceable (essential) fatty acids. Class polyunsaturated fatty acids an omega-3 promote change of liquid properties of membranes of cells and increase in functional activity of membrane receptors that improves lipidic and cellular interaction of lipoproteids with enzymes and metabolism of lipoproteids. Detain synthesis of triglycerides in a liver (at the expense of inhibition of etherification of fatty acids). Decrease in level of triglycerides is promoted also by increase by peroxide P beta oxidations of fatty acids (reduction of amount of free fatty acids, available for synthesis of triglycerides).

Increase in LPVP is very insignificant and is not constant. It is much less, than after reception of fibrat.

Antiagregantny effect of drug is connected with change under its influence of structure of lipids of cellular membranes, including membranes of erythrocytes, reduction of contents in them arachidonic acid and increase in level of eykozapentayenovy acid. Thereof there is a decrease in synthesis of A2 thromboxane and other two-unsaturated eicosanoids (derivatives of arachidonic acid) strengthening aggregation of thrombocytes and increase in synthesis from eykozapentayenovy acid of a tormboksan A3 and other trinenasyshchenny eicosanoids which are not possessing proagregantny action. The expressed changes of other blood-coagulation factors are not observed. Kardiotropny action is peculiar to drug. It is caused by antiarrhytmic action of PNZhK which increased quantity in a lipidic bislo of membranes of cardiomyocytes promotes more effective function of cation pompes, sharply reduces quantity of cases of ventricular tachycardias and fibrillation of heart and prevents disturbances of electric stability of heart at a postinfarction cardiosclerosis.

Pharmacokinetics. In time and after absorption the omega-3 of fatty acids metabolism occurs on three ways:
- fatty acids at first are delivered in a liver where are included various categories of lipoproteids and go to peripheral stocks of lipids;
- phospholipids of cellular membranes are replaced with phospholipids of lipoproteids then fatty acids can act as predecessors of various eicosanoids;
- the majority of fatty acids is oxidized for the purpose of ensuring energy needs.

Concentration of eykozapentayenovy and dokozageksayenovy acids in phospholipids of a blood plasma corresponds to concentration of these fatty acids included in structure of cellular membranes.

Indications to use:

Indications to use of Omekord-Mick medicine are:
- secondary prevention of a myocardial infarction (as a part of a combination therapy with statines, antitrombotichesky means, beta adrenoblockers, APF inhibitors);
- giperlipoproteinemiya;
- an endogenous gipertriglitseridemiya (type IV on Fredrikson's classification) as monotherapy in addition to a diet at its insufficient efficiency;
- the mixed lipidemia (the IIb and III types on Fredrikson's classification (in a combination with statines in case concentration of triglycerides remains high).

Route of administration and doses:

The Omekord-Mick capsules are recommended to be accepted inside during food. For secondary prevention of a myocardial infarction about 2 capsules in days are recommended to accept. At a gipertriglitseridemiya the initial dose makes 4 capsules a day. In case of lack of therapeutic effect increase in a dose up to 8 capsules in days is possible. Treatment duration – according to the recommendation of the doctor.

Features of use:

Due to the moderate increase in a bleeding time (at reception of high doses) observation of the patients undergoing anticoagulating therapy, and if necessary – the corresponding dose adjustment of anticoagulant is required.

It is necessary to take into consideration increase in a bleeding time at patients with the increased risk of a hemorrhage (as a result of a severe injury, surgery, etc.).

The available experience of the research of a secondary endogenous gipertriglitseridemiya (which is especially not giving in to control of a diabetes mellitus) is limited.

There is no clinical experience in the relation of treatment of a gipertriglitseridemiya in combination with fibrata.

At administration of drug perhaps moderate increase in activity of "hepatic" transaminases. At patients with an abnormal liver function (especially at reception of high doses) regular control of function of a liver is necessary (nuclear heating plant and ALT).

Data on use of drug for children, elderly patients are more senior than 70 years or at patients with abnormal liver functions are absent.

With a renal failure of dose adjustment it is not required from patients.

Side effects:

Frequency of side effects is distributed in the following order: often (in 1% - 10% of cases), infrequently (in 0,1% - 1% of cases); seldom (in 0,01% - 0,1% of cases); very seldom (less than 0,01%), including messages on single side effects.
From digestive tract: often dyspepsia, nausea; vomiting, a reflux or an eructation with a smell or smack of fish.

From a respiratory organs: very seldom dryness in a nose.

Vascular disorders: the lowering of arterial pressure is very rare.

From a nervous system: infrequently dizziness, dysgeusia (food faddism); seldom – a headache.

From immune system: infrequently hypersensitivity.

Disbolism and food: seldom hyperglycemia.

From a liver: seldom disturbances of a liver.

From skin and a hypodermic fatty tissue: seldom eels, pruritic rashes; very seldom – a small tortoiseshell.

Infectious processes: infrequently gastroenteritis.

Interaction with other medicines:

At simultaneous use with peroral anticoagulants the risk of increase in a bleeding time increases.

Omekorda-Mick together with warfarin does not lead appointment to any hemorrhagic complications. However at the combined reception Omekorda-Mick and warfarin or the termination of a course of treatment Omekordom-Mick is necessary control of a prothrombin time.

The concomitant use from fibrata is not recommended.

Contraindications:

- hypersensitivity to drug components;

- exogenous gipertriglitseridemiya (hyper chylomicronemia of type 1);

- pregnancy and period of a lactation.

Overdose:

Symptoms: emergence of side effects or strengthening of their expressiveness is possible.

Treatment: symptomatic, drug withdrawal.

Storage conditions:

Store in the place protected from moisture and light at a temperature from 15 °C to 25 °C. Period of validity 2 years.

Issue conditions:

Without recipe

Packaging:

On 10 capsules in blister strip packagings, on 3 or 6 strip packagings in a cardboard box.